These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Chemotherapeutic tumour targeting using clostridial spores. Minton NP; Mauchline ML; Lemmon MJ; Brehm JK; Fox M; Michael NP; Giaccia A; Brown JM FEMS Microbiol Rev; 1995 Oct; 17(3):357-64. PubMed ID: 7576773 [TBL] [Abstract][Full Text] [Related]
4. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945 [TBL] [Abstract][Full Text] [Related]
5. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Bridgewater JA; Knox RJ; Pitts JD; Collins MK; Springer CJ Hum Gene Ther; 1997 Apr; 8(6):709-17. PubMed ID: 9113510 [TBL] [Abstract][Full Text] [Related]
6. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641 [TBL] [Abstract][Full Text] [Related]
7. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2. Mitchell DJ; Minchin RF Cancer Gene Ther; 2008 Nov; 15(11):758-64. PubMed ID: 18600257 [TBL] [Abstract][Full Text] [Related]
8. Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. Liu SC; Ahn GO; Kioi M; Dorie MJ; Patterson AV; Brown JM Cancer Res; 2008 Oct; 68(19):7995-8003. PubMed ID: 18829557 [TBL] [Abstract][Full Text] [Related]
9. Identification of novel nitroreductases from Bacillus cereus and their interaction with the CB1954 prodrug. Gwenin VV; Poornima P; Halliwell J; Ball P; Robinson G; Gwenin CD Biochem Pharmacol; 2015 Dec; 98(3):392-402. PubMed ID: 26415543 [TBL] [Abstract][Full Text] [Related]
10. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals. Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794 [TBL] [Abstract][Full Text] [Related]
11. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Drabek D; Guy J; Craig R; Grosveld F Gene Ther; 1997 Feb; 4(2):93-100. PubMed ID: 9081711 [TBL] [Abstract][Full Text] [Related]
12. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. Lukashev AN; Fuerer C; Chen MJ; Searle P; Iggo R Hum Gene Ther; 2005 Dec; 16(12):1473-83. PubMed ID: 16390278 [TBL] [Abstract][Full Text] [Related]
13. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Lemmon MJ; van Zijl P; Fox ME; Mauchline ML; Giaccia AJ; Minton NP; Brown JM Gene Ther; 1997 Aug; 4(8):791-6. PubMed ID: 9338007 [TBL] [Abstract][Full Text] [Related]
14. A mammalianized synthetic nitroreductase gene for high-level expression. Grohmann M; Paulmann N; Fleischhauer S; Vowinckel J; Priller J; Walther DJ BMC Cancer; 2009 Aug; 9():301. PubMed ID: 19712451 [TBL] [Abstract][Full Text] [Related]
15. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy. Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235 [TBL] [Abstract][Full Text] [Related]
16. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391 [TBL] [Abstract][Full Text] [Related]
17. Virus-directed enzyme prodrug therapy using CB1954. Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268 [TBL] [Abstract][Full Text] [Related]
18. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy. Blackwood L; O'Shaughnessy PJ; Reid SW; Argyle DJ Vet J; 2001 May; 161(3):269-79. PubMed ID: 11352484 [TBL] [Abstract][Full Text] [Related]
19. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Weedon SJ; Green NK; McNeish IA; Gilligan MG; Mautner V; Wrighton CJ; Mountain A; Young LS; Kerr DJ; Searle PF Int J Cancer; 2000 Jun; 86(6):848-54. PubMed ID: 10842200 [TBL] [Abstract][Full Text] [Related]
20. Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours. Mowday AM; Dubois LJ; Kubiak AM; Chan-Hyams JVE; Guise CP; Ashoorzadeh A; Lambin P; Ackerley DF; Smaill JB; Minton NP; Theys J; Patterson AV Cancer Gene Ther; 2022 Feb; 29(2):178-188. PubMed ID: 33558701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]